Cigna Strikes Deals With Lilly, Novo for Obesity Coverage (2)

Cigna Group has struck deals with obesity drug makers Eli Lilly & Co. and Novo Nordisk A/S that aim to widen coverage by limiting how much employer-sponsored health plans have to pay for the medicines.

The agreements by the company’s pharmacy benefits manager are part of a pitch to employers alarmed by spiking costs for popular new weight-loss treatments including Novo’s Wegovy and Lilly’s Zepbound. Cigna says its program will limit spending increases for the class of drugs, known as GLP-1s, to a maximum of 15% annually. The company called it the first such financial guarantee on the market.

The ...